BioInvent's BI-1808-Keytruda Combination Shows 24% Response Rate in Platinum-Resistant Ovarian Cancer Trial

• BioInvent reported durable responses with BI-1808 combined with Keytruda in heavily pretreated patients with platinum-resistant ovarian cancer.
• Updated results covering 34 evaluable patients were presented at the ESMO Congress in Madrid on October 24, 2026.
• The chemotherapy-free regimen was generally well tolerated, with manageable immune-related side effects and few treatment-related discontinuations.
• A randomized trial will test BI-1808 added to pembrolizumab and weekly paclitaxel, with optional bevacizumab, against that treatment backbone alone.
• The next stage will enroll 20 patients per arm across three groups, starting in Q1 2027; initial data are expected in H2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioInvent International AB published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.